At last check on Wednesday, Applied Genetic Technologies Corporation (AGTC) has gained 13.91% after hours to trade at $4.75. AGTC stock closed the regular trading session at $4.17, climbing just 0.72%. Applied Genetic stock volume was 4.66 million shares, higher than the average daily volume of 1.2 million shares for the past 50 days.
Over the last 12 months, AGTC shares fell by -38.22%, and they declined by -4.14% just last week. AGTC stock has shed -17.75% over past quarter, and in the last six months, it has faced a loss of -7.74%. Additionally, AGTC has a market capitalization of $176.64 million and 36.75 million outstanding shares. AGTC stock rose as the company announced it would hold a conference call.
What will AGTC discuss in its conference call?
Applied The clinical-stage biotechnology company Applied Genetic develops treatments in the field of genetics for ophthalmic, otologic, and central nervous system (CNS) diseases. As part of its mission to develop customized therapies, AGTC designs and constructs all critical elements of gene therapy. Clinical programs developed by AGTC can potentially improve the vision of patients with retinal genetic diseases by using its top-of-the-line technology platform.
Achromatopsia (ACHM CNGB3 and ACHM CNGA3) and X-linked retinitis pigmentosa (XLRP) are clinical trials that the AGTC is currently conducting. The Company has developed industry leading AAV production technology and scientific expertise that support its preclinical program. As part of its pipeline, AGTC is moving ahead with a number of pipeline candidates targeting unmet clinical needs in the fields of optogenetics, otology, and neurological diseases.
Applied On Thursday, June 24, 2021, Applied Genetics plans to release 12-month data for its Phase 1/2 clinical Achromatopsia (ACHM) trials that include adults and low-dose pediatric patients.
Starting at 8:00 a.m. Eastern Time, AGTC management will host a conference call and webcast. ACHM CNGB3 and CNGA3 trial data will be reviewed by AGTC on the same date, and an update on the trials will be provided.
AGTC’s Investor Relations page will offer access to the live webcast on the Events and Presentations page. AGTC’s website will have the archived presentation and webcast available under Events & Presentations.
AGTC’s other participations:
Applied Genetic (AGTC) also announced this week that its Executive Director of Global Patient Advocacy, Jill Dolgin, PharmD, will attend the 124th Annual American Optometric Association Congress & 51st Annual American Optometric Student Association Conference. At that meeting on June 24-26 in Denver, the AGTC’s executive will address optometric graduate students regarding inherited retinal diseases (IRDs).
